The Pioneer and Daiichi Sankyo Golden Ticket
Pioneer Group has partnered with global healthcare company Daiichi Sankyo to launch a Golden Ticket designed to help accelerate innovations in novel therapeutic platform technologies, oncology, neuroscience and ophthalmology.
The Golden Ticket programme is aimed at early-stage biotech companies focused on novel drug targets and transformational medicines, with robust research plans and potential for successful research development.
Are you passionate about making a difference in the fields of:
Novel modalities & technologies
- RNA-targeting therapeutics
- Drug delivery technologies for targeting organs & cells
- Proximity inducing modalities
- Protein/cell/virus/genetic engineering technologies
Oncology
- Novel tumour-specific therapeutic modalities with a unique approach or mechanism, and unique methods for discovering tumour-specific binders
Speciality medicine
- Novel research for identifying disease-relevant targets using patient tissue samples in central nervous system and ophthalmology
Applications for the Daiichi Sankyo x Pioneer Group Accelerator Prize close 30 May 2025. Learn more about the application process.